In the recently published meta-analysis titled “Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis”, Huang et al. compared the efficacy and safety of treatment with colistin monotherapy versus colistin plus meropenem combination therapy in patients with drug-resistant Acinetobacter baumannii infection [1]. This comment addresses an error in the results of the published meta-analysis. The study included ten publications—three were reported as randomized controlled trials (RCTs) and seven as retrospective studies. All three “RCTs” were one trial including the same patients. The publication by Paul et al. described the results of the trial [2]. The other two studies were observational sub-studies: Dickstein et al. performed an exploratory subgroup analysis of the trial [3], and Nutman et al. tested the association between the presence of in vitro synergism and the trials’ clinical outcomes [4]. This is clearly reported in the secondary publications of the trial [3,4]. All three studies represent the same trial, but they were entered into the forest plots as if they were three different RCTs, repeatedly including the same patients, and creating a ‘unit-of-analysis error’, resulting in an exaggerated weight to the meta-analysis [5].
Another trial that should be mentioned is the OVERCOME trial by Kaye K. et al.: ‘Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)’. The trial results were not fully published yet but are available online on ClinicalTrials.gov [6].
In summary, the results of the meta-analysis should be corrected to include one report of the RCT by Paul et al. In addition, mentioning the OVERCOME trials’ results should be considered.
Author Contributions
Conceptualization—V.D., M.P. and L.L.; writing—original draft preparation, V.D.; writing—review and editing, M.P. and L.L. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
Funding Statement
This research received no external funding.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Huang C., Chen I., Tang T. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. J. Clin. Med. 2022;11:3239. doi: 10.3390/jcm11113239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Paul M., Daikos G.L., Durante-Mangoni E., Yahav D., Carmeli Y., Benattar Y.D., Skiada A., Andini R., Eliakim-Raz N., Nutman A., et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial. Lancet Infect. Dis. 2018;18:391–400. doi: 10.1016/S1473-3099(18)30099-9. [DOI] [PubMed] [Google Scholar]
- 3.Dickstein Y., Lellouche J., Amar M.B.D., Schwartz D., Nutman A., Daitch V., Yahav D., Leibovici L., Skiada A., Antoniadou A., et al. AIDA Study Group. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clin. Infect. Dis. 2019;69:769–776. doi: 10.1093/cid/ciy988. [DOI] [PubMed] [Google Scholar]
- 4.Nutman A., Lellouche J., Temkin E., Daikos G., Skiada A., Durante-Mangoni E., Dishon-Benattar Y., Bitterman R., Yahav D., Daitch V., et al. AIDA Study Group. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes. Clin. Microbiol. Infect. 2020;26:1185–1191. doi: 10.1016/j.cmi.2020.03.035. [DOI] [PubMed] [Google Scholar]
- 5.Higgins J.P.T., Eldridge S., Li T., editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; London, UK: 2022. Chapter 23: Including variants on randomized trials. Version 6.3. [Google Scholar]
- 6.Kaye K. Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME). ClinicalTrials.gov identifier: NCT01597973. Updated on 30 November 2021. [(accessed on 1 November 2022)]; Available online: https://clinicaltrials.gov/ct2/show/study/NCT01597973.